Literature DB >> 12213884

IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo.

J Rubin1, C L Ackert-Bicknell, L Zhu, X Fan, T C Murphy, M S Nanes, R Marcus, L Holloway, W G Beamer, C J Rosen.   

Abstract

IGF-I, a ubiquitous polypeptide, plays a key role in longitudinal bone growth and acquisition. The most predominant effect of skeletal IGF-I is acceleration of the differentiation program for osteoblasts. However, in vivo studies using recombinant human (rh) IGF-I and/or rhGH have demonstrated stimulation of both bone formation and resorption, thereby potentially limiting the usefulness of these peptides in the treatment of osteoporosis. In this study, we hypothesized that IGF-I modulates bone resorption by regulating expression of osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB (RANK) ligand (RANKL) in bone cells. Using Northern analysis in ST2 cells, we found that human IGF-I suppressed OPG mRNA in a time- and dose-dependent manner: 100 micro g/LIGF-I (13 nM) decreased OPG expression by 37.0 +/- 1.8% (P < 0.002). The half maximal inhibitory dose of IGF-I was reached at 50 micro g/liter ( approximately 6.5 nM) with no effect of IGF-I on OPG message stability. Conditioned media from ST2 cells confirmed that IGF-I decreased secreted OPG, reducing levels by 42%, from 12.1-7 ng/ml at 48 h (P < 0.05). Similarly, IGF-I at 100 micro g/liter (13 nM) increased RANKL mRNA expression to 353 +/- 74% above untreated cells as assessed by real-time PCR. In vivo, low doses of rhGH when administered to elderly postmenopausal women only modestly raised serum IGF-I (to concentrations of 18-26 nM) and did not affect circulating OPG concentrations; however, administration of rhIGF-I (30 micro g/kg.d) for 1 yr to older women resulted in a significant increase in serum IGF-I (to concentrations of 39-45 nM) and a 20% reduction in serum OPG (P < 0.05). In summary, we conclude that IGF-I in a dose- and time-dependent manner regulates OPG and RANKL in vitro and in vivo. These data suggest IGF-I may act as a coupling factor in bone remodeling by activating both bone formation and bone resorption; the latter effect appears to be mediated through the OPG/RANKL system in bone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213884     DOI: 10.1210/jc.2002-020656

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions.

Authors:  Shoshana Yakar; Ernesto Canalis; Hui Sun; Wilson Mejia; Yuki Kawashima; Philip Nasser; Hayden-William Courtland; Valerie Williams; Mary Bouxsein; Clifford Rosen; Karl J Jepsen
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741

Review 2.  Systems analysis of bone.

Authors:  Karl J Jepsen
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2009 Jul-Aug

3.  The role of nitric oxide in the mechanical repression of RANKL in bone stromal cells.

Authors:  Jill Rahnert; Xian Fan; Natasha Case; Tamara C Murphy; Francesco Grassi; Buer Sen; Janet Rubin
Journal:  Bone       Date:  2008-03-20       Impact factor: 4.398

4.  Index radial collateral ligament repair with titanium mini-suture anchor: osteolysis complication of an underreported injury.

Authors:  Ather Mirza; Mary Kate Reinhart; Joseph John Bove
Journal:  Hand (N Y)       Date:  2009-10-14

Review 5.  Biochemical Changes in the Niche Following Tumor Cell Invasion.

Authors:  A M Decker; F C Cackowski; Y Jung; R S Taichman
Journal:  J Cell Biochem       Date:  2017-04-18       Impact factor: 4.429

6.  Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?

Authors:  A Gaudio; A Lasco; N Morabito; M Atteritano; C Vergara; A Catalano; W Fries; A Trifiletti; N Frisina
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

7.  Regulation of osteogenic differentiation by DNA methylation of the dishevelled gene in bone marrow mesenchymal stem cells.

Authors:  Xiaofeng Han; Xinfeng Li; Guibin Zhong; Zude Liu
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

8.  Association between circulating levels of adiponectin and indices of bone mass and bone metabolism in middle-aged post-menopausal women.

Authors:  R Tenta; M D Kontogianni; N Yiannakouris
Journal:  J Endocrinol Invest       Date:  2011-05-23       Impact factor: 4.256

9.  Effects of titanium particle size on osteoblast functions in vitro and in vivo.

Authors:  Moon G Choi; Hae S Koh; Daniel Kluess; Daniel O'Connor; Anshu Mathur; George A Truskey; Janet Rubin; David X F Zhou; K-L Paul Sung
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-08       Impact factor: 11.205

10.  Bone metabolism compensates for the delayed growth in small for gestational age neonates.

Authors:  Roxane Tenta; Ifigeneia Bourgiezi; Evangelos Aliferis; Magdalini Papadopoulou; Antonis Gounaris; Maria Skouroliakou
Journal:  Organogenesis       Date:  2013-01-01       Impact factor: 2.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.